These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 33369374)

  • 1. [The use of long-acting somatostatin analogs in congenital hyperinsulinism].
    Novokreshhennyx EE; Gubaeva DN; Melikyan MA
    Probl Endokrinol (Mosk); 2020 Oct; 66(5):70-78. PubMed ID: 33369374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Continuous subcutaneous infusion of somatostatin analogues in the treatment of congenital hyperinsulinism].
    Melikyan MA; Gubaeva DN; Kareva MA
    Probl Endokrinol (Mosk); 2020 Sep; 66(3):81-87. PubMed ID: 33351342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Long-Acting Somatostatin Analogue (Lanreotide) in an Adolescent with Diazoxide-Responsive Congenital Hyperinsulinism and Its Psychological Impact.
    Shah P; Rahman SA; McElroy S; Gilbert C; Morgan K; Hinchey L; Senniappan S; Levy H; Amin R; Hussain K
    Horm Res Paediatr; 2015; 84(5):355-60. PubMed ID: 26375451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Use of a Long-Acting Somatostatin Analogue (Lanreotide) in Three Children with Focal Forms of Congenital Hyperinsulinaemic Hypoglycaemia.
    Dastamani A; Güemes M; Pitfield C; Morgan K; Rajab M; Rottenburger C; Bomanji J; De Coppi P; Dattani M; Shah P
    Horm Res Paediatr; 2019; 91(1):56-61. PubMed ID: 30114684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with long-acting lanreotide autogel in early infancy in patients with severe neonatal hyperinsulinism.
    Corda H; Kummer S; Welters A; Teig N; Klee D; Mayatepek E; Meissner T
    Orphanet J Rare Dis; 2017 Jun; 12(1):108. PubMed ID: 28576129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of octreotide for the treatment of congenital hyperinsulinism: a prospective, open-label clinical trial and an observational study in Japan using a nationwide registry.
    Hosokawa Y; Kawakita R; Yokoya S; Ogata T; Ozono K; Arisaka O; Hasegawa Y; Kusuda S; Masue M; Nishibori H; Sairenchi T; Yorifuji T
    Endocr J; 2017 Sep; 64(9):867-880. PubMed ID: 28701683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of congenital hyperinsulinism with lanreotide acetate (Somatuline Autogel).
    Modan-Moses D; Koren I; Mazor-Aronovitch K; Pinhas-Hamiel O; Landau H
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2312-7. PubMed ID: 21697252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Use of Lanreotide in the Treatment of Congenital Hyperinsulinism.
    Cuff H; Lord K; Ballester L; Scully T; Stewart N; De Leon DD
    J Clin Endocrinol Metab; 2022 Jul; 107(8):e3115-e3120. PubMed ID: 35587448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Multicenter Experience with Long-Acting Somatostatin Analogues in Patients with Congenital Hyperinsulinism.
    van der Steen I; van Albada ME; Mohnike K; Christesen HT; Empting S; Salomon-Estebanez M; Greve Rasmussen A; Verrijn Stuart A; van der Linde AAA; Banerjee I; Boot AM
    Horm Res Paediatr; 2018; 89(2):82-89. PubMed ID: 29241206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoxetine-Induced Hypoglycaemia in a Patient with Congenital Hyperinsulinism on Lanreotide Therapy.
    Giri D; Price V; Yung Z; Didi M; Senniappan S
    J Clin Res Pediatr Endocrinol; 2016 Sep; 8(3):347-50. PubMed ID: 27087264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term medical treatment in congenital hyperinsulinism: a descriptive analysis in a large cohort of patients from different clinical centers.
    Welters A; Lerch C; Kummer S; Marquard J; Salgin B; Mayatepek E; Meissner T
    Orphanet J Rare Dis; 2015 Nov; 10():150. PubMed ID: 26608306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term lanreotide treatment in six patients with congenital hyperinsulinism.
    Kühnen P; Marquard J; Ernert A; Meissner T; Raile K; Wannenmacher G; Blankenstein O
    Horm Res Paediatr; 2012; 78(2):106-12. PubMed ID: 22907123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conservatively treated Congenital Hyperinsulinism (CHI) due to K-ATP channel gene mutations: reducing severity over time.
    Salomon-Estebanez M; Flanagan SE; Ellard S; Rigby L; Bowden L; Mohamed Z; Nicholson J; Skae M; Hall C; Craigie R; Padidela R; Murphy N; Randell T; Cosgrove KE; Dunne MJ; Banerjee I
    Orphanet J Rare Dis; 2016 Dec; 11(1):163. PubMed ID: 27908292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of congenital hyperinsulinism with long-acting release octreotide.
    Le Quan Sang KH; Arnoux JB; Mamoune A; Saint-Martin C; Bellanné-Chantelot C; Valayannopoulos V; Brassier A; Kayirangwa H; Barbier V; Broissand C; Fabreguettes JR; Charron B; Thalabard JC; de Lonlay P
    Eur J Endocrinol; 2012 Feb; 166(2):333-9. PubMed ID: 22048969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Octreotide-related exocrine pancreatic insufficiency (EPI) in congenital hyperinsulinism.
    Ros-Pérez P; Golmayo L; Cilleruelo ML; Gutiérrez C; Celaya P; Lacámara N; Martínez-Badás I; Güemes M; Argente J
    J Pediatr Endocrinol Metab; 2020 Jul; 33(7):947-950. PubMed ID: 32634108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
    Verhelst JA; Pedroncelli AM; Abs R; Montini M; Vandeweghe MV; Albani G; Maiter D; Pagani MD; Legros JJ; Gianola D; Bex M; Poppe K; Mockel J; Pagani G
    Eur J Endocrinol; 2000 Nov; 143(5):577-84. PubMed ID: 11078980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical management of diazoxide-unresponsive congenital hyperinsulinism: A single-center experience.
    Takasawa K; Iemura R; Orimoto R; Yamano H; Kirino S; Adachi E; Saito Y; Yamamoto K; Matsuda N; Takishima S; Shuno K; Tajima H; Sugie M; Mizuno Y; Sutani A; Okamoto K; Masue M; Morio T; Kashimada K
    Clin Pediatr Endocrinol; 2024; 33(3):187-194. PubMed ID: 38993725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
    Chanson P; Boerlin V; Ajzenberg C; Bachelot Y; Benito P; Bringer J; Caron P; Charbonnel B; Cortet C; Delemer B; Escobar-Jiménez F; Foubert L; Gaztambide S; Jockenhoevel F; Kuhn JM; Leclere J; Lorcy Y; Perlemuter L; Prestele H; Roger P; Rohmer V; Santen R; Sassolas G; Scherbaum WA; Schopohl J; Torres E; Varela C; Villamil F; Webb SM
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nifedipine in Congenital Hyperinsulinism - A Case Report.
    Khawash P; Hussain K; Flanagan SE; Chatterjee S; Basak D
    J Clin Res Pediatr Endocrinol; 2015 Jun; 7(2):151-4. PubMed ID: 26316440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.